SCHEMBL4473853

SCHEMBL4473853

CCC(C)OP(=O)(O)C(F)F

nearest known ligand 0.33

Predicted protein targets (top 8)

geneUniProtsupporting neighboursconfidence
LAP3 P28838 3/20 0.33
METAP1 P53582 1/20 0.32
MMP1 P03956 1/20 0.32
MMP2 P08253 1/20 0.32
MMP3 P08254 1/20 0.32
CTSA P10619 1/20 0.31
ACHE P22303 1/20 0.31
SMPD1 P17405 3/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19245350 0.80 TRPM8 (0.35) LAP3METAP1MMP1MMP2MMP3
SCHEMBL10755198 0.78 LAP3 (0.33) LAP3METAP1MMP1MMP2MMP3
SCHEMBL3175491 0.78 LAP3 (0.43) LAP3METAP1
SCHEMBL3926688 0.77 POLB (0.33)
SCHEMBL28389061 0.77
SCHEMBL8347462 0.77 LAP3 (0.52) LAP3METAP1
Methane SCHEMBL3938662 0.77 LAP3 (0.32) LAP3METAP1MMP1MMP2MMP3
SCHEMBL485995 0.77
SCHEMBL497286 0.77 LAP3 (0.39) LAP3METAP1MMP1MMP2MMP3
SCHEMBL5382476 0.76 KDM4E (0.32) LAP3ACHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4615847-A1 SMALL MOLECULE INHIBITORS OF KRAS PROTEINS Merck Sharp & Dohme LLC (US) 2025-09-17 EP disclosed
US-20240228446-A1 PREPARATION METHOD FOR BICYCLIC COMPOUND AND APPLICATION AS ANTIFUNGAL AGENT SHANGHAI JEMINCARE PHARMACEUTICAL CO., LTD (CN) 2024-07-11 US disclosed
WO-2024103010-A1 SMALL MOLECULE INHIBITORS OF KRAS PROTEINS MERCK SHARP & DOHME LLC (US) 2024-05-16 WO disclosed
EP-4317139-A1 PREPARATION METHOD FOR BICYCLIC COMPOUND AND APPLICATION AS ANTIFUNGAL AGENT Shanghai Jemincare Pharmaceuticals Co., Ltd. (CN) 2024-02-07 EP disclosed
US-7579469-B2 Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) 2009-08-25 US disclosed
EP-1583745-A1 1-PROPANOL AND 1-PROPYLAMINE DERIVATIVES AND THEIR USE AS GLUCOCORTICOID LIGANDS BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) 2005-10-12 EP disclosed
US-20040162321-A1 Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. 2004-08-19 US disclosed
WO-2004063163-A1 1-PROPANOL AND 1-PROPYLAMINE DERIVATIVES AND THEIR USE AS GLUCOCORTICOID LIGANDS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) 2004-07-29 WO disclosed
EP-0479640-A2 Novel phosphonate derivatives of certain nucleosides MERRELL DOW PHARMACEUTICALS INC. (US) 1992-04-08 EP disclosed
EP-0477454-A1 Novel phosphonate derivatives of certain nucleosides MERRELL DOW PHARMACEUTICALS INC. (US) 1992-04-01 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240228446-A1 PREPARATION METHOD FOR BICYCLIC COMPOUND AND APPLICATION AS ANTIFUNGAL AGENT ERG28, CYP51A1, DPM1 LAP3 1299/4885METAP1 1199/4885MMP1 2217/4885
US-20040162321-A1 Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof NR3C1, NR3C2, MC2R LAP3 1951/4885METAP1 749/4885MMP1 731/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.